Association between serum complements and kidney function in patients with diabetic kidney disease.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2023
Historique:
received: 29 03 2023
accepted: 30 10 2023
medline: 5 12 2023
pubmed: 4 12 2023
entrez: 4 12 2023
Statut: epublish

Résumé

We aimed to explore the association between serum complements and kidney function of diabetic kidney disease (DKD) in Chinese patients. This is a retrospective study involving 2,441 participants. DKD was diagnosed according to the Kidney Disease: Improving Global Outcomes (KDIGO) categories. Participants were classified as stages G1-G5 by KDIGO glomerular filtration rate (GFR) categories. Effect sizes are expressed as odds ratio (OR) with 95% confidence interval (CI). After balancing age, gender, systolic blood pressure (SBP), hemoglobin A1c (HbA1C), serum triglyceride (TG), and urinary albumin-to-creatinine ratio (UACR) between the G2-G5 and control groups, per 0.1 g/L increment in serum complement C3 was significantly associated with a 27.8% reduced risk of DKD at G5 stage (OR, 95% CI, P: 0.722, 0.616-0.847, <0.001) relative to the G1 stage. Conversely, per 0.1 g/L increment in serum complement C4 was associated with an 83.0-177.6% increased risk of G2-G5 stage (P<0.001). Serum complement C1q was not statistically significant compared to controls at all stages prior to or after propensity score matching. Our results indicate that high concentrations of serum C4 were associated with the significantly elevated risk of kidney function deterioration across all stages, and reduced serum C3 levels with an increased risk of DKD stage G5.

Identifiants

pubmed: 38047115
doi: 10.3389/fendo.2023.1195966
pmc: PMC10690951
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1195966

Informations de copyright

Copyright © 2023 Liu, Li, Wang, Meng, Zheng, Cai, Shen, Wang, Zhu, Chen, Wang, Zhao, Niu and Wang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Endocrinol (Lausanne). 2019 Jul 09;10:459
pubmed: 31338070
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
BMC Immunol. 2018 Jun 20;19(1):18
pubmed: 29925312
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
J Diabetes. 2022 Apr;14(4):291-297
pubmed: 35322566
Hypertension. 2018 Jun;71(6):e13-e115
pubmed: 29133356
Kidney Int. 2021 Jan;99(1):256-266
pubmed: 32891604
Lancet Oncol. 2021 Sep;22(9):1333-1340
pubmed: 34399096
Nat Rev Nephrol. 2017 May;13(5):311-318
pubmed: 28262777
Metabolism. 2015 May;64(5):597-610
pubmed: 25682062
Diabetes Metab J. 2016 Dec;40(6):473-481
pubmed: 27766790
Front Immunol. 2020 Sep 02;11:2073
pubmed: 32983156
Epidemiology. 2010 Jan;21(1):128-38
pubmed: 20010215
BMJ Open Diabetes Res Care. 2019 Nov 15;7(1):e000817
pubmed: 31798904
Kidney Int Rep. 2017 Oct 16;3(2):302-313
pubmed: 29725633
Kidney Int Rep. 2019 Mar 20;4(6):797-805
pubmed: 31194090
Front Med (Lausanne). 2021 Jan 21;7:599236
pubmed: 33553201
Am J Nephrol. 2015;41(1):48-56
pubmed: 25662584
Nat Rev Nephrol. 2016 Jul;12(7):383-401
pubmed: 27211870
Front Endocrinol (Lausanne). 2022 Apr 22;13:869899
pubmed: 35528010
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045
pubmed: 28522654
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Cochrane Database Syst Rev. 2017 Jun 08;6:CD010137
pubmed: 28594069
J Clin Med. 2020 May 26;9(6):
pubmed: 32466507
Front Immunol. 2022 May 27;13:868127
pubmed: 35711407
Acta Diabetol. 2018 Jan;55(1):31-39
pubmed: 29043511
Nat Rev Nephrol. 2020 Apr;16(4):206-222
pubmed: 31942046
JCI Insight. 2020 Mar 12;5(5):
pubmed: 32161193
Front Pharmacol. 2022 Apr 14;13:872988
pubmed: 35548353
Semin Nephrol. 2021 Mar;41(2):96-103
pubmed: 34140100

Auteurs

Meng-Chao Liu (MC)

The First Clinical Medical College, Beijing University of Chinese Medicine, Beijing, China.
Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Jia-Lin Li (JL)

Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Yue-Fen Wang (YF)

Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Yuan Meng (Y)

Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Gui-Min Zheng (GM)

Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Zhen Cai (Z)

Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Cun Shen (C)

Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Meng-di Wang (MD)

Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Xiang-Gang Zhu (XG)

Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Yang-Zi Chen (YZ)

Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Yu-Lin Wang (YL)

Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Wen-Jing Zhao (WJ)

Department of Nephropathy, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Wen-Quan Niu (WQ)

Center for Evidence-Based Medicine, Capital Institute of Pediatrics, Beijing, China.

Yao-Xian Wang (YX)

The First Clinical Medical College, Beijing University of Chinese Medicine, Beijing, China.
Henan University of Chinese Medicine, Zhengzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH